Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 2

Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer  treatment and/or higher doses?

Authors Rahman S, Ismail AA, Ismail SB, Naing NN, Rahman ARA

Published 20 April 2010 Volume 2010:2 Pages 83—87

DOI https://doi.org/10.2147/CPAA.S8863

Review by Single-blind

Peer reviewer comments 2


Sayeeda Rahman1, Aziz Al-Shafi Ismail2, Shaiful Bhari Ismail3, Nyi Nyi Naing4, Abdul Rashid Abdul Rahman5

1Department of Clinical Sciences, School of Life Sciences, University of Bradford, Bradford, UK; 2Department of Community Medicine, 3Department of Family Medicine, 4Unit of Biostatistics and Research Methodology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia; 5Cyberjaya University College of Medical Sciences 63000 Cyberjaya Malaysia, Malaysia

Introduction: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients.

Methods: In this randomized, double-blind, placebo-controlled study, 33 T2DM patients were randomized to rosiglitazone (4 mg/daily) or ramipril (5 mg/daily) or placebo for 1 year. Hemodynamic variables were measured at 3 treatment phases and pulse wave velocity (PWV) and augmentation index (AI) were measured throughout the treatment period.

Result: In diabetic patients, PWV (P = 0.037) and AI (P = 0.005) with ramipril and AI (P < 0.001) with rosiglitazone were significantly reduced during overall treatment period from the baseline; however, these differences were not significant in comparison to placebo.

Discussion and conclusion: The present study showed that treatment with standard doses of rosiglitazone and ramipril are not adequate to reverse pre-clinical vasculopathy in T2DM. The lack of benefit in newly diagnosed T2DM may be because of the relatively short-term intervention and/or the use of lower doses of rosiglitazone/ramipril. Further trials are needed for a longer period of time, possibly with higher doses, to show whether rosiglitazone/ramipril can reverse pre-clinical vasculopathy in T2DM (ClinicalTrials.gov number, NCT00489229).
Keywords: rosiglitazone, ramipril, diabetic vasculopathy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]